AKT1 and neoplasm: The synergy between the PI3K-AKT pathway and various chemotherapeutic agents, including doxorubicin, etoposide, topotecan, cisplatin, vincristine, and taxol, is well-documented, leading to heightened tumor sensitivity to chemotherapy.